microRNA-133: Expression, function and therapeutic potential in muscle diseases and cancer

Current Drug Targets

Volumn 15, Issue 9, 2014, Pages 817-828

  Yu, Hao ^a   Lu, Yinhui ^a   Li, Zhaofa ^a   Wang, Qizhao ^b  

^a HUAQIAO UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Gene therapy; microRNA 133; Muscle development

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 133A 1; MICRORNA 133A 2; MICRORNA 133B; MICRORNA 206; UNCLASSIFIED DRUG; MIRN133 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; BIOGENESIS; BLADDER CANCER; CARCINOGENICITY; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; HEART ARRHYTHMIA; HEART CONDUCTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HUMAN; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCULAR DYSTROPHY; NEOPLASM; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; ANIMAL; GENETICS; METABOLISM; MUSCULAR DISEASES; NEOPLASMS;

ANIMALS; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOCARDIUM; NEOPLASMS;

EID: 84906919311     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140627104151     Document Type: Review

References (131)

1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
2. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked byadenosine, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
3. Doench JG, Sharp PA. Specificity of microRNA target selection in translation repression. Genes Dev 2004; 18: 504-11.
4. Grey F, Tirabassi R, Meyers H, Wu G, et al. A viral microRNA down-regulates multiple cell cycle genes through mRNA 5'UTRs. PLoS Pathog 2010; 6: e1000967.
5. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455: 1124-8.
6. Storz G, Opdyke JA, Zhang A. Controlling mRNA stability and translation with small, noncoding RNAs. Curr Opin Microbiol 2004; 7: 140-4.
7. Careton M, Cleary MA, LInsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007; 6: 2127-32.
8. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113(6): 673-6. Epub 2003/06/18.
9. Dresios J, Aschrafi A, Owens GC, Vanderklish PW, Edelman GM, Mauro VP. Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters microRNA levels, and enhances global protein synthesis. Proc Natl Acad Sci USA 2005; 102(6): 1865-70.
10. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259-69.
11. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004; 5(3): R13.
12. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38(2): 228-33.
13. Szafranska A, Davison T, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007; 26(30): 4442-52.
14. McCarthy JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 2008; 1779(11): 682-91.
15. van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. Trends Genet 2008; 24(4): 159-66.
16. Liu N, William AH, Kim Y, et al. An intragenic MEF2-dependent enhancer directs muscle-specificexpression of microRNAs 1 and 133. Proc Natl Acad Sci USA 2007; 104(52): 20844-9.
17. Niu Z, Li A, Zhang SX, Schwartz RJ. Serum response factor micromanaging cardiogenesis. Curr Opin Cell Biol 2007; 19(6): 618-27.
18. Rao PK, Kumar R, Farkhondeh M, Baskerville S, Lodish HF. Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci USA 2006; 103(23): 8721-6.
19. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 436(7048): 214-20.
20. McKinsey TA, Zhang CL, Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol 2002; 14(6): 763-72.
21. Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development 2007; 134(23): 4131-40.
22. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13(5): 613-8.
23. McCarthy JJ, Esser KA, Peterson CA, Dupont-Versteegden EE. Evidence of MyomiR network regulation of β-myosin heavy chain gene expression during skeletal muscle atrophy. Physiol Genomics 2009; 39(3): 219-26.
24. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Musclespecific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174(5): 677-87.
25. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ. MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 2006; 175(1): 77-85.
26. Boutz PL, Chawla G, Stoilov P, Black DL. MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev 2007; 21(1): 71-84.
27. Xu C, Lu Y, Pan Z, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120(17): 3045-52.
28. Ivey KN, Muth A, Arnold J, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2008; 2(3): 219-29.
29. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: Critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 2010; 42(8): 1252-5.
30. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129(2): 302-17.
31. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008; 105(6): 2111-6.
32. Wienholds E, Kloosterman WP, Miska E, et al. MicroRNA expression in zebrafish embryonic development. Science 2005; 309(5732): 310-1.
33. Kwon C, Han Z, Olson EN, Srivastava D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci USA 2005; 102(52): 18986-91.
34. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129(2): 303-17.
35. Sokol NS, Ambros V. Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth. Genes Dev 2005; 19(19): 2343-54.
36. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008; 22(23): 3242-54.
37. Sprenkle AB, Murray SF, Glembotski CC. Involvement of Multiple cis Elements in Basal-and α-Adrenergic Agonist-Inducible Atrial Natriuretic Factor Transcription Roles for Serum Response Elements and an SP-1-Like Element. Circ Res 1995; 77(6): 1060-9.
38. Nelson TJ, Balza Jr. R, Xiao Q, Misra RP. SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J Mol Cell Cardiol 2005; 39(3): 479-89.
39. Zhang X, Azhar G, Chai J, et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol 2001; 280(4): H1782-H92.
40. Ruzicka DL, Schwartz RJ. Sequential activation of alpha-actin genes during avian cardiogenesis: vascular smooth muscle alphaactin gene transcripts mark the onset of cardiomyocyte differentiation. J Cell Biol 1988; 107(6): 2575-86.
41. McHugh KM. Molecular analysis of smooth muscle development in the mouse. Dev Dyn 1995; 204(3): 278-90.
42. Li L, Miano JM, Cserjesi P, Olson EN. SM22α, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res 1996; 78(2): 188-95.
43. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 2005; 96(1): 110-8.
44. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13(4): 486-91.
45. Luo X, Xiao J, Lin H, et al. Retracted: Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of IKs-encoding genes and potential implications in regional heterogeneity of their expressions. J Cell Physiol 2007; 212(2): 358-67.
46. Xiao J, Luo X, Lin H, et al. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007; 282(17): 12363-7.
47. Luo X, Lin H, Pan Z, et al. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008; 283(29): 20045-52.
48. Subcommittee SS. AHA statistical update. Circulation. 2007; 115: e69-e171.
49. Ahmad F, Seidman J, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005; 6: 185-216.
50. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115(3): 527-37.
51. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature 2008; 451(7181): 919-28.
52. Sayed D, Hong C, Chen I-Y, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100(3): 416-24.
53. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103(48): 18255-60.
54. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170(6): 1831-40.
55. Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42(6): 1137-41.
56. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current Biology 2002; 12(9): 735-9.
57. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101(12): 1225-36.
58. Mann DL, Bristow MR. Mechanisms and models in heart failure the biomechanical model and beyond. Circulation 2005; 111(21): 2837-49.
59. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the Human Heart A Clue to Fetal Gene Reprogramming in Heart Failure. Circulation 2007; 116(3): 258-67.
60. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 2007; 102(1): 306-13.
61. McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol 2007; 293(1): c451-7.
62. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010; 106(1): 166-75.
63. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame a decade of hypertrophic signaling hits. Circ Res 2006; 98(6): 730-42.
64. Ke Y, Wang L, Pyle WG, de Tombe PP, Solaro RJ. Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circ Res 2004; 94(2): 194-200.
65. Xu C, Lu Y, Pan Z, et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007; 120(17): 3045-52.
66. Wells A, Kim H, Kassis J, Souto J, Turner T. EGF receptor signaling in prostate morphogenesis and tumorigenesis. Histol Histopathol 1999; 14(4): 1175-82.
67. Bauersachs J, Thum T. MicroRNAs in the broken heart. Eur J Clin Invest 2007; 37(11): 829-33.
68. Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31(3): 367-73.
69. Lee T-C, Shi Y, Schwartz RJ. Displacement of BrdUrd-induced YY1 by serum response factor activates skeletal alpha-actin transcription in embryonic myoblasts. Proc Natl Acad Sci USA 1992; 89(20): 9814-8.
70. Karamboulas C, Swedani A, Ward C, et al. HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage. J Cell Sci 2006; 119(20): 4305-14.
71. Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007; 100(8): 1164-73.
72. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99(24): 15524-9.
73. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65(21): 9628-32.
74. Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65(16): 7065-70.
75. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65(14): 6029-33.
76. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2005; 25(17): 2537-45.
77. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102(52): 19075-80.
78. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103(10): 3687-92.
79. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68(13): 5049-58.
80. Nasser MW, Datta J, Nuovo G, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008; 283(48): 33394-405.
81. Yan D, Dong XDE, Chen X, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009; 284(43): 29596-604.
82. Uchida Y, Chiyomaru T, Enokida H, et al. editors. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier.
83. Childs G, Fazzari M, Kung G, et al. Low-Level Expression of MicroRNAs let-7d and miR-205 Are Prognostic Markers of Head and Neck Squamous Cell Carcinoma. Am J Pathol 2009; 174(3): 736-45.
84. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Retracted: Novel approaches for gene-specific interference via manipulating actions of microRNAs: Examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007; 212(2): 285-92.
85. Esau CC, Monia BP. Therapeutic potential for microRNAs. Adv Drug Deliv Rev 2007; 59(2): 101-14.
86. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
87. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
88. Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102(5): 883-91.
89. Chiyomaru T, Enokida H, Kawakami K, et al., editors. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urologic Oncology: Seminars and Original Investigations; 2012: Elsevier.
90. Yoshino H, Chiyomaru T, Enokida H, et al. The tumoursuppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 2011; 104(5): 808-18.
91. Yamasaki T, Yoshino H, Enokida H, et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol 2012; 40(6): 1821-30.
92. Uchida Y, Chiyomaru T, Enokida H, et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol-Semin Ori 2013; 31(1): 115-23.
93. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-49.
94. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Actas Urológicas Españolas (English Edition) 2011; 35(10): 565-79.
95. Wang L, Tang H, Thayanithy V, et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009; 69(24): 9490-7.
96. Traish A, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 2009; 101(12): 1949-56.
97. Tao J, Wu D, Xu B, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 2012; 27(6): 1967-75.
98. Hernes E, Fosså S, Berner A, Otnes B, Nesland J. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90(2): 449-54.
99. Kharait S, Dhir R, Lauffenburger D, Wells A. Protein kinase Cδ signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2006; 343(3): 848-56.
100. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010; 29(35): 4947-58.
101. Rao PK, Missiaglia E, Shields L, et al. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 2010; 24(9): 3427-37.
102. Moriya Y, Nohata N, Kinoshita T, et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2012; 57(1): 38-45.
103. Nohata N, Hanazawa T, Kikkawa N, et al. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol 2011; 39(5): 1099-107.
104. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008; 123(2): 251-7. Epub 2008/05/09.
105. Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127(12): 2804-14.
106. Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012; 48(6): 827-36.
107. Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10(2): 190-7.
108. Moriya Y, Nohata N, Kinoshita T, et al. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2011; 57(1): 38-45.
109. Nohata N, Hanazawa T, Kikkawa N, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 2011; 38(1): 209-17.
110. Chiyomaru T, Enokida H, Tatarano S, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102(5): 883-91.
111. Mutallip M, Nohata N, Hanazawa T, et al. Glutathione Stransferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC). Int J Mol Med 2011; 27(3): 345-52.
112. Uchida Y, Chiyomaru T, Enokida H, et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 2013; 31(1): 115-23.
113. Chiyomaru T, Enokida H, Kawakami K, et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 2012; 30(4): 434-43.
114. Kojima S, Chiyomaru T, Kawakami K, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2012; 106(2): 405-13.
115. Nohata N, Sone Y, Hanazawa T, et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2011; 2(1-2): 29-42.
116. Crawford M, Batte K, Yu L, et al. MicroRNA 133B targets prosurvival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009; 388(3): 483-9.
117. Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics 2009; 25(23): 3049-55.
118. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol 2006; 2(1): 46.
119. Shalgi R, Lieber D, Oren M, Pilpel Y. Global and local architecture of the mammalian microRNA-transcription factor regulatory network. PLoS Comput Biol 2007; 3(7): e131.
120. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55(1): 10-30.
121. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54(1): 73-87.
122. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7(6): 759-64.
123. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104(40): 15805-10.
124. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41: 9-14.
125. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41: 29-42.
126. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7(7): 1850-5.
127. Rusch V, Klimstra D, Venkatraman E, Pisters P, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3(4): 515-22.
128. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284(1): 122-30.
129. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53(10): 2379-85.
130. Krützfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007; 35(9): 2885-92.
131. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438(7068): 685-9.